Physician profile
Ingrid M Hoffmann
NPI 1386634541
$8,648.31
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,120 · 2020: $926 · 2021: $1,952 · 2022: $1,740 · 2023: $1,012 · 2024: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.50 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,269.75 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Optinose US, INC. | $816.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $770.62 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $684.30 | 2019-2024 | Dupixent |
| Genzyme Corporation | $462.28 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $449.62 | 2019-2024 | |
| Pfizer INC. | $303.09 | 2019-2024 | |
| Genentech USA, INC. | $294.74 | 2019-2023 | Xolair |
| Abbvie INC. | $232.61 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.16 | 2020-2023 | Takhzyro |
| Janssen Pharmaceuticals, INC | $175.54 | 2020-2021 | |
| Kaleo, INC. | $123.53 | 2021-2022 | |
| Incyte Corporation | $115.03 | 2021 | |
| Shire North American Group INC | $111.76 | 2019 | |
| Grifols USA, LLC | $111.54 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $94.85 | 2023-2024 | Tezspire |
| Csl Behring | $91.73 | 2019-2020 | |
| Hospira, INC. | $89.30 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $83.66 | 2021 | |
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Covis Pharma Gmbh | $49.82 | 2022 | |
| Leo Pharma INC. | $20.78 | 2022 | |
| Uswm, LLC | $14.00 | 2021 | |
| Alk-Abello, INC | $13.32 | 2023 | Ragwitek, Odactra, Grastek |
| Sunovion Pharmaceuticals INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.